Ruthenium-based chemotherapeutics: Are they ready for prime time?

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 1, 2010, Pages 1-9

  Antonarakis, Emmanuel S ^a   Emadi, Ashkan ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chemotherapy; KP1019; NAMI A; ONCO4417; Ruthenium

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; DW 1; GRANISETRON; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; NAMI A; ONCO 4417; RAPTA C; RAPTA T; RM 175; RUTHENIUM DERIVATIVE; UNCLASSIFIED DRUG; DIMETHYL SULFOXIDE; DRUG DERIVATIVE; IMIDAZOLIUM BIS(IMIDAZOLE)DIMETHYLSULFOXIDEIMIDAZOTETRACHLORORUTHENATE(III); IMIDAZOLIUM-BIS(IMIDAZOLE)DIMETHYLSULFOXIDEIMIDAZOTETRACHLORORUTHENATE(III); INDAZOLE DERIVATIVE; KP1019; NEW DRUG; ORGANOMETALLIC COMPOUND;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; BLADDER CARCINOMA; BLISTER; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CANCER; DIARRHEA; DNA ADDUCT; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG URINE LEVEL; ENANTIOMER; ENDOMETRIUM CARCINOMA; FATIGUE; HUMAN; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; INJECTION SITE PHLEBITIS; IRON BINDING CAPACITY; LOW DRUG DOSE; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; OVARY CANCER; OXIDATION; PANCREAS CANCER; PERIPHERAL EDEMA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SHORT SURVEY; SIDE EFFECT; STOMATITIS; TINNITUS; TOXICITY TESTING; TREATMENT DURATION; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; ANIMAL; CHEMISTRY; DRUG SCREENING; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DIMETHYL SULFOXIDE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, INVESTIGATIONAL; HUMANS; INDAZOLES; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; RUTHENIUM COMPOUNDS;

EID: 77649266052     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1293-1     Document Type: Short Survey

References (66)

1. Galanski M, Jakupec MA, Keppler BK (2005) Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem 12:2075-2094
2. Galanski M (2006) Recent developments in the field of anticancer platinum complexes. Recent Pat Anticancer Drug Discov 1:285-295
3. Brabec V, Kasparkova J (2005) Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 8:131-146
4. Ott I, Gust R (2007) Non platinum metal complexes as anti-cancer drugs. Arch Pharm (Weinheim) 340:117-126
5. Sava G, Bergamo A (2009) Ruthenium drugs for cancer chemotherapy: an ongoing challenge to treat solid tumours. In: Bonetti A et al (eds) Platinum and other heavy metal compounds in cancer chemotherapy. Humana Press, New York, pp 57-66. doi:10.1007/978-1-60327-459-3
6. Kostova I (2006) Ruthenium complexes as anticancer agents. Curr Med Chem 13:1085-1107
7. Heffeter P, Jungwirth U, Jakupec M, Hartinger C, Galanski M et al (2008) Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updat 11:1-16
8. Sava G, Zorzet S, Giraldi T, Mestroni G, Zassinovich G (1984) Antineoplastic activity and toxicity of an organometallic complex of ruthenium (II) in comparison with cis-PDD in mice bearing solid malignant neoplasms. Eur J Cancer Clin Oncol 20:841-847
9. Sava G, Bergamo A (2000) Ruthenium-based compounds and tumour growth control (review). Int J Oncol 17:353-365
10. Schluga P, Hartinger CG, Egger A, Reisner E, Galanski M et al (2006) Redox behavior of tumor-inhibiting ruthenium (III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans 14:1796-1802
11. Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT (2009) Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med 9:442-458
12. 4 (DMSO) Im] in the mouse. Clin Exp Metastasis 12:93-100
13. Bergamo A, Masi A, Dyson PJ, Sava G (2008) Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int J Oncol 33:1281-1289
14. Sava G, Alessio E, Bergamo A, Mestroni G (1999) Sulfoxide ruthenium complexes. Top Biol Inorg Chem 1:143-169
15. Pieper T, Borsky K, Keppler BK (1999) Non-platinum antitumor compounds. Top Biol Inorg Chem 1:171-199
16. 4 (DMSO) Im], a metal complex of ruthenium with antimetastatic properties. Clin Exp Metastasis 10:273-280
17. Sava G, Pacor S, Bergamo A, Cocchietto M, Mestroni G et al (1995) Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition. Chem Biol Interact 95:109-126
18. Jakupec MA, Arion VB, Kapitza S, Reisner E, Eichinger A et al (2005) KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development-an overview. Int J Clin Pharmacol Ther 43:595-596
19. Hartinger CG, Jakupec MA, Zorbas-Seifried S, Groessl M, Egger A et al (2008) KP1019, a new redox-active anticancer agentpreclinical development and results of a clinical phase I study in tumor patients. Chem Biodivers 5:2140-2155
20. Clarke MJ, Zhu F, Frasca DR (1999) Non-platinum chemotherapeutic metallopharmaceuticals. Chem Rev 99:2511-2534
21. Bloemink MJ, Reedijk J (1996) Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Met Ions Biol Syst 32:641-685
22. Reedijk J (2003) New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc Natl Acad Sci USA 100:3611-3616
23. Yamada H, Koike T, Hurst JK (2001) Water exchange rates in the diruthenium μ-oxo ion cis, cis-[(bpy) 2Ru (OH) 2]2O4+. J Am Chem Soc 123:12775-12780
24. Chakravarty J, Bhattacharya S (1996) Ruthenium phenolates. Synthesis, characterization and electron-transfer properties of some salicylaldiminato and 2-(arylazo) phenolato complexes of ruthenium. Polyhedron 15:1047-1055
25. Baitalik S, Adhikary B (1997) Heterochelates of ruthenium (II) : electrochemistry, absorption spectra, and luminescence properties. Polyhedron 16:4073-4080
26. Kratz F, Messori L (1993) Spectral characterization of ruthenium (III) transferrin. J Inorg Biochem 49:79-82
27. Pongratz M, Schluga P, Jakupec MA, Arion VB, Hartinger CG et al (2004) Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy. J Anal At Spectrom 19:46-51
28. Mestroni G, Alessio E, Sava G (1998) International Patent PCT C 07F 15/00, A61 K 31/28, WO 98/0043
29. Bergamo A, Gagliardi R, Scarcia V, Furlani A, Alessio E et al (1999) In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J Pharmacol Exp Ther 289:559-564
30. 2-M cell fraction and inhibition of matrigel invasion, may predict in vivoselective antimetastasis activity of ruthenium complexes. J Pharmacol Exp Ther 295:927-933
31. Vacca A, Bruno M, Boccarelli A, Coluccia M, Ribatti D et al (2002) Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A. Br J Cancer 86:993-998
32. Pluim D, van Waardenburg RC, Beijnen JH, Schellens JH (2004) Cytotoxicity of the organic ruthenium anticancer drug NAMI-A is correlated with DNA binding in four different human tumor cell lines. Cancer Chemother Pharmacol 54:71-78
33. Sava G, Gagliardi R, Bergamo A, Alessio E, Mestroni G (1999) Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine. Anticancer Res 19:969-972
34. Sava G, Capozzi I, Clerici K, Gagliardi G, Alessio E et al (1998) Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Clin Exp Metastasis 16:371-379
35. 4 (DM-SO) Im]: mechanism of the selective action investigated on mouse tumors. Anticancer Drugs 10:129-138
36. Cocchietto M, Sava G (2000) Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice. Pharmacol Toxicol 87:193-197
37. Rademaker-Lakhai JM, van den Bongard D, Pluim D, Beijnen JH, Schellens JH (2004) A Phase I and pharmacological study with imidazolium-trans-DMSO- imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res 10:3717-3727
38. Brouwers EE, Tibben MM, Rosing H, Schellens JH, Beijnen JH (2007) Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry. Rapid Commun Mass Spectrom 21:1521-1530
39. Galanski M, Arion VB, Jakupec MA, Keppler BK (2003) Recent developments in the field of tumor-inhibiting metal complexes. Curr Pharm Des 9:2078-2089
40. Kapitza S, Pongratz M, Jakupec MA, Heffeter P, Berger W et al (2005) Heterocyclic complexes of ruthenium (III) induce apoptosis in colorectal carcinoma cells. J Cancer Res Clin Oncol 131:101-110
41. Kapitza S, Jakupec MA, Uhl M, Keppler BK, Marian B (2005) The heterocyclic ruthenium (III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett 226:115-121
42. 14A). J Pharmacol Exp Ther 312:281-289
43. 14A). J Inorg Biochem 100:891-904
44. 14A) in a phase I dose-escalation study. Anticancer Drugs 20:97-103
45. 14A) in patients with solid tumors. Int J Clin Pharmacol Ther 47:58-60
46. Morris RE, Aird RE, Murdoch Pdel S, Chen H, Cummings J et al (2001) Inhibition of cancer cell growth by ruthenium (II) arene complexes. J Med Chem 44:3616-3621
47. Chen H, Parkinson JA, Parsons S, Coxall RA, Gould RO et al (2002) Organometallic ruthenium (II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogenbonding in guanine adducts. J Am Chem Soc 124:3064-3082
48. Chen H, Parkinson JA, Morris RE, Sadler PJ (2003) Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms. J Am Chem Soc 125:173-186
49. Hayward RL, Schornagel QC, Tente R, Macpherson JS, Aird RE et al (2005) Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium (II) organometallic agent, RM175. Cancer Chemother Pharmacol 55:577-583
50. Gaiddon C, Jeannequin P, Bischoff P, Pfeffer M, Sirlin C et al (2005) Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. J Pharmacol Exp Ther 315:1403-1411
51. Aird RE, Cummings J, Ritchie AA, Muir M, Morris RE et al (2002) In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. Br J Cancer 86:1652-1657
52. Foster RE, Cole DA, Mead S, Sadler PJ, Grimshaw KM (2009) Investigation into the mechanism of action of the ruthenium (II) organometallic complex, ONCO 4417. In: Proceedings of the American association for cancer research, April 18-22: Abstract 889
53. Scolaro C, Bergamo A, Brescacin L, Delfino R, Cocchietto M et al (2005) In vitro and in vivo evaluation of ruthenium (II)-arene PTA complexes. J Med Chem 48:4161-4171
54. 6-arene imidazole complexes. J Med Chem 49:5552-5561
55. Scolaro C, Geldbach TJ, Rochat S (2006) Influence of hydrogenbonding substituents on the cytotoxicity of RAPTA compounds. Organometallics 25:756-765
56. Scolaro C, Chaplin AB, Hartinger CG, Bergamo A, Cocchietto M et al. (2007) Tuning the hydrophobicity of ruthenium (II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. Dalton Trans 43:5065-5072
57. Chatterjee S, Kundu S, Bhattacharyya A, Hartinger CG, Dyson PJ (2008) The ruthenium (II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. J Biol Inorg Chem 13:1149-1155
58. 2CS, n = 2]. Eur J Inorg Chem 19:3034-3046
59. 2 with N-N = bpy, phen, dpq, dppz, and dppn. Chem Med Chem 3:1104-1109
60. Meggers E, Atilla-Gokcumen GE, Bregman H, Maksimoska J, Mulcahy SP et al (2007) Exploring chemical space with organometallics: ruthenium complexes as protein kinase inhibitors. Synlett 8:1177-1189
61. Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE et al (2007) An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res 67:209-217
62. Debreczeni JE, Bullock AN, Atilla GE, Williams DS, Bregman H et al (2006) Ruthenium half-sandwich complexes bound to protein kinase Pim-1. Angew Chem Int Ed Engl 45:1580-1585
63. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M et al (2005) Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 105:1759-1767
64. Adam M, Pogacic V, Bendit M, Chappuis R, Nawijn MC et al (2006) Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. Cancer Res 66:3828-3835
65. US Department of Health and Human Services Food and Drug Administration (2004) Innovation or stagnation: challenges and opportunity on the critical path to new medical products. http://www.fda.gov/oc/initiatives/criticalpath/ whitepaper.html [last accessed 02/05/2010]
66. LoRusso PM (2009) Phase 0 clinical trials: an answer to drug development stagnation? J Clin Oncol 27:2586-2588